ReviewCardio-oncology (London, England)2026
Cardioprotective strategies of ACEi/ARBs and beta-blockers against anthracycline-induced cardiotoxicity in pediatric cancer survivors: a systematic review.
Review in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnthracyclines are routinely used in pediatric oncology but cause dose-dependent cardiotoxicity that compromises long-term survival. Neurohormonal agents such as ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), and beta-blockers have been suggested as preventive or therapeutic agents, yet evidence in children remains limited. Present review aimed to synthesize available data on their efficacy and safety among this population.
methodA systematic search of PubMed, Scopus, and Web of Science was conducted from inception to August 2025. Eligible studies included pediatric cancer survivors exposed to anthracyclines who received ACEi, ARBs, or beta-blockers with reported cardiac outcomes. Data extraction and risk-of-bias assessments were performed independently by two reviewers. Findings were synthesized narratively owing to study heterogeneity.
findingsSixteen studies met inclusion criteria, comprising nine RCTs, three observational studies, two case series, and two case reports. ACEi, mainly enalapril and captopril, were associated with attenuation of left ventricular ejection fraction (LVEF) decline and reduced biomarker elevations, although long-term benefits were inconsistent and side effects such as hypotension were reported. Beta-blockers, particularly carvedilol, improved ventricular function, strain indices, and clinical symptoms in several studies, though the largest trial (PREVENT-HF) did not show significant benefit on primary remodeling outcomes, except in high-risk subgroups. Overall, the evidence suggests that while preventive use of ACEi/ARBs and beta-blockers shows more consistent benefits, findings regarding their role in reversing established cardiotoxicity remain variable and should be interpreted cautiously.
conclusionACEi/ARBs and beta-blockers showed promise in preventing or mitigating anthracycline-induced cardiotoxicity among children, with consistent benefits on surrogate outcomes but uncertain durability and survival impact. Early initiation and targeted use in high-risk patients appear most advantageous, underscoring the need for large biomarker-guided trials to refine prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.